Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
ln Vivo |
In 4 month old male C57Bl6 mice, a single intravenous injection of TAT-Gap19 (55 mg/kg) causes a substantial immunological signal in the brain 24 hours later[1]. Mice treated with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks demonstrate considerably reduced collagen deposition and lowed quantities of α-SMA-positive cell area with TAT-Gap19 (1 mg/kg/day), an osmotic pump implanted in the peritoneal cavity[2].
|
---|---|
References |
[1]. Verónica Abudara, et al. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014 Oct 21;8:306.
[2]. Sara Crespo Yanguas, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3):817. [3]. Laura Walrave, et al. Inhibition of astroglial connexin43 hemichannels with TAT-Gap19 exerts anticonvulsant effects in rodents. Glia. 2018 Aug;66(8):1788-1804. |
Molecular Formula |
C119H212N46O26
|
---|---|
Molecular Weight |
2703.25
|
CAS # |
1507930-54-2
|
Related CAS # |
TAT-Gap19 TFA
|
SMILES |
O=C([C@H]([C@@H](C)CC)NC([C@H](CCC(=O)O)NC([C@H]([C@@H](C)CC)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(=N)N)NC([C@H](CCCNC(=N)N)NC([C@H](CCCNC(=N)N)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(=N)N)NC([C@H](CCCNC(=N)N)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CCCNC(=N)N)NC(CNC([C@H](CC1C=CC(=CC=1)O)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CCCCN)=O)CC1C=CC=CC=1)=O)CCCCN)=O)CCCCN
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : 50 mg/mL (18.50 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (36.99 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.3699 mL | 1.8496 mL | 3.6993 mL | |
5 mM | 0.0740 mL | 0.3699 mL | 0.7399 mL | |
10 mM | 0.0370 mL | 0.1850 mL | 0.3699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.